눈베체트병과 HLA-B51의 연관성

소개글

눈베체트병과 HLA-B51의 연관성에 대한 보고서 자료입니다.

목차

Ⅰ. 서 론

Ⅱ. 임상 증상
진단 기준
베체트병에서 눈 병변(Ocular lesion)
-눈 베체트병의 특징 및 임상양상
-눈 베체트병의 예후
-눈 베체트병의 국내 연구 조사 결과

Ⅲ. 베체트병과 HLA-B51의 연관성
눈 베체트병과 HLA-B51의 연관성
눈 베체트병의 예후와 HLA-B51의 연관성

Ⅳ. 토론(discussion) 및 결론(conclusion)

본문내용

from patients with Behcet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995;38:426-33
29) Yamashita N. Hyperreactiity of neutrophils and abnormal T cell homeostasis : a new insight for pathogenesis of Behcet's disease. Int Rev Immunol 1997;14:11-9
30) Ersoy F, Berkel Al, Firat T, Kazokoglu H. HLA antigens associated with Behcet's disease. Arch Dermatol 1977;133:1720-21
31) Adorno D, Pezzi PP, Bonini S, et al. HLA-B and Behcet's disease. Tissue Antigens 1979;14:444-8
32) Lee SN, Koh YJ, Kim DH, et al. A study of HLA antigen in Behcet's Syndrome. Yonsei Med J 1988;29:259-62
33) Gul A, Uyar FA, Inanc M, et al. Lack of association of HLA-B51 with severe disease course in Behcet's disease. Rheumatology 2001;40:668-72
34) Sakane T, Suzuki N, Nagafuchi H. Etiopathology of Behcet's disease : Immunological Aspects. Yonsei Med J 1997;38:350-8
35) 오정우, 김민호, 유진성, 허원. 한국인 포도막염환자의 HLA 항원분석. 한안지 1999;40:104-9
36) 장현규, 김정욱, 천경수. 베체트병에서 nested PCR amplification을 이용한 HLA-B51 항원 분석. 대한내과학회지 1999;57:241-2
37) 정흠. 베체트병의 안 증상. 대한내과학회지 1998;55;541-5
38) 이윤우. 베체트병의 치료(베체트병의 단계별 치료). 대한내과학회지 1998;55:545-50
39) Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet 1989;1:1093-6
40) Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndreome. N Eng J Med 1990;322:281-5
41) Yazici H, Yurdakul S, Hamuryudan V. Behcet's disease. Curr Opin Rheumatol 2001;13:18-22
42) 황정희, 신성영. 만성 베체트병 환자에서 종양괴사인자 단일세포군항체를 이용한 치료 3예. 한안지 2005;46:1405-10
43) Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight threatening panuveitis in Behcet's Disease. Lancet 2001;358:295-6
44) Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefe's Arch Clin Exp Ophthalmol 2005;243:1147-52
45) Sakamoto M, Akazawa K, Nishioka Y, et al. Prognostic factor of vision in patients with Behcet's disease. Ophthalmology 1995;102:317-21
46) Ahn JK, Park YG. Human Leukocyte Antigen B27 and B51 double-positive Behcet uveitis. Arch Ophthalmol 2007;125:1375-80
47) Gul A, Hajeer AH, Worthington J, et al. Linkage mapping of a novel susceptibility locus for Behcet's disease to chromosome 6p22-23. Arthritis Rheum 2001;44:2693-6
48) Gul A, Hajeer AH, Worthington J, et al. Evidence for linkage of the HLA-B5 locus in Behcet's disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001;44:239-40
49) Sant SM, Kilmartin D, Acheson RA. HLA antigens in familial Behcet's disease in Ireland. Br J RHeumatol 1998;37:1250-1
50) Deuter ME, Kotter I, Wallace GR. Behcet's disease : Ocular effects and treatment. Prog Retin Eye Res 2008;27:111-136
Fig 1. World distribution of HLA-B51
Reprinted from Verity DH, Marr JE, Ohno , et al. Behcet's disease, the Silk Road and HLA-B51:historical and geographical perspectives. Tissue Antigens 1999;54:213-20

키워드

베체트,   베체트병,   눈베체트병,   HLA-B51,   HLA